nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—hypertension—obesity	0.376	1	CtDrD
Methyldopa—COMT—obesity	0.199	1	CbGaD
Methyldopa—Levonordefrin—Phenylpropanolamine—obesity	0.164	1	CrCrCtD
Methyldopa—ADRA2A—Benzphetamine—obesity	0.0581	0.363	CbGbCtD
Methyldopa—ADRA2A—Phenylpropanolamine—obesity	0.0554	0.346	CbGbCtD
Methyldopa—ADRA2A—Methamphetamine—obesity	0.0465	0.29	CbGbCtD
Methyldopa—DDC—hindbrain—obesity	0.00141	0.143	CbGeAlD
Methyldopa—DDC—respiratory system—obesity	0.000864	0.0873	CbGeAlD
Methyldopa—COMT—islet of Langerhans—obesity	0.000605	0.0612	CbGeAlD
Methyldopa—COMT—respiratory system—obesity	0.000571	0.0577	CbGeAlD
Methyldopa—DDC—adrenal gland—obesity	0.000523	0.0529	CbGeAlD
Methyldopa—COMT—adrenal cortex—obesity	0.000479	0.0485	CbGeAlD
Methyldopa—DDC—endocrine gland—obesity	0.000454	0.0459	CbGeAlD
Methyldopa—COMT—cardiovascular system—obesity	0.000438	0.0442	CbGeAlD
Methyldopa—DDC—liver—obesity	0.000409	0.0414	CbGeAlD
Methyldopa—SLC15A1—digestive system—obesity	0.000408	0.0413	CbGeAlD
Methyldopa—Toxic epidermal necrolysis—Cimetidine—obesity	0.000401	0.00747	CcSEcCtD
Methyldopa—COMT—pituitary gland—obesity	0.000387	0.0392	CbGeAlD
Methyldopa—COMT—adipose tissue—obesity	0.000386	0.039	CbGeAlD
Methyldopa—Amenorrhoea—Orlistat—obesity	0.000386	0.00718	CcSEcCtD
Methyldopa—Pancytopenia—Diethylpropion—obesity	0.000384	0.00716	CcSEcCtD
Methyldopa—Pancreatitis—Cimetidine—obesity	0.000378	0.00703	CcSEcCtD
Methyldopa—Amenorrhoea—Sibutramine—obesity	0.000373	0.00695	CcSEcCtD
Methyldopa—Erectile dysfunction—Diethylpropion—obesity	0.000373	0.00694	CcSEcCtD
Methyldopa—Joint swelling—Topiramate—obesity	0.000372	0.00692	CcSEcCtD
Methyldopa—Pancytopenia—Cimetidine—obesity	0.000366	0.00681	CcSEcCtD
Methyldopa—COMT—digestive system—obesity	0.000363	0.0367	CbGeAlD
Methyldopa—Isoprenaline—PIK3R1—obesity	0.000355	0.144	CrCbGaD
Methyldopa—Erectile dysfunction—Cimetidine—obesity	0.000355	0.0066	CcSEcCtD
Methyldopa—COMT—adrenal gland—obesity	0.000346	0.035	CbGeAlD
Methyldopa—Liver injury—Bupropion—obesity	0.00034	0.00633	CcSEcCtD
Methyldopa—SLC15A1—endocrine gland—obesity	0.000337	0.0341	CbGeAlD
Methyldopa—Agranulocytosis—Diethylpropion—obesity	0.000337	0.00627	CcSEcCtD
Methyldopa—Amenorrhoea—Bupropion—obesity	0.000325	0.00606	CcSEcCtD
Methyldopa—Agranulocytosis—Cimetidine—obesity	0.000321	0.00597	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methamphetamine—obesity	0.000318	0.00592	CcSEcCtD
Methyldopa—Nightmare—Sibutramine—obesity	0.000317	0.0059	CcSEcCtD
Methyldopa—Constipation—Methamphetamine—obesity	0.000315	0.00586	CcSEcCtD
Methyldopa—Colitis—Sibutramine—obesity	0.000315	0.00586	CcSEcCtD
Methyldopa—Bradycardia—Cimetidine—obesity	0.000314	0.00584	CcSEcCtD
Methyldopa—Hepatitis—Cimetidine—obesity	0.000308	0.00574	CcSEcCtD
Methyldopa—ADRA2A—islet of Langerhans—obesity	0.000308	0.0311	CbGeAlD
Methyldopa—Gastrointestinal disorder—Benzphetamine—obesity	0.000307	0.00571	CcSEcCtD
Methyldopa—SLC15A1—liver—obesity	0.000304	0.0308	CbGeAlD
Methyldopa—COMT—endocrine gland—obesity	0.0003	0.0303	CbGeAlD
Methyldopa—Hepatocellular injury—Bupropion—obesity	0.000286	0.00532	CcSEcCtD
Methyldopa—Constipation—Phendimetrazine—obesity	0.000277	0.00515	CcSEcCtD
Methyldopa—Nightmare—Bupropion—obesity	0.000276	0.00514	CcSEcCtD
Methyldopa—Colitis—Bupropion—obesity	0.000275	0.00511	CcSEcCtD
Methyldopa—Eczema—Orlistat—obesity	0.000274	0.0051	CcSEcCtD
Methyldopa—Hypersensitivity—Methamphetamine—obesity	0.000271	0.00505	CcSEcCtD
Methyldopa—COMT—liver—obesity	0.000271	0.0274	CbGeAlD
Methyldopa—Bone marrow depression—Topiramate—obesity	0.00027	0.00502	CcSEcCtD
Methyldopa—Eczema—Sibutramine—obesity	0.000265	0.00493	CcSEcCtD
Methyldopa—Oedema—Phentermine—obesity	0.000265	0.00493	CcSEcCtD
Methyldopa—Flatulence—Cimetidine—obesity	0.000264	0.00492	CcSEcCtD
Methyldopa—Cardiac failure congestive—Sibutramine—obesity	0.000263	0.00489	CcSEcCtD
Methyldopa—Hypersensitivity—Benzphetamine—obesity	0.000262	0.00487	CcSEcCtD
Methyldopa—Nasal congestion—Sibutramine—obesity	0.000261	0.00487	CcSEcCtD
Methyldopa—Libido decreased—Sibutramine—obesity	0.000257	0.00478	CcSEcCtD
Methyldopa—Gynaecomastia—Bupropion—obesity	0.000256	0.00476	CcSEcCtD
Methyldopa—Leukopenia—Diethylpropion—obesity	0.000253	0.0047	CcSEcCtD
Methyldopa—Diarrhoea—Methamphetamine—obesity	0.000252	0.00469	CcSEcCtD
Methyldopa—Dizziness—Methamphetamine—obesity	0.000244	0.00453	CcSEcCtD
Methyldopa—Diarrhoea—Benzphetamine—obesity	0.000243	0.00452	CcSEcCtD
Methyldopa—Leukopenia—Cimetidine—obesity	0.00024	0.00447	CcSEcCtD
Methyldopa—Myalgia—Diethylpropion—obesity	0.00024	0.00447	CcSEcCtD
Methyldopa—Constipation—Phenylpropanolamine—obesity	0.000236	0.0044	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Sibutramine—obesity	0.000236	0.0044	CcSEcCtD
Methyldopa—Dizziness—Benzphetamine—obesity	0.000235	0.00437	CcSEcCtD
Methyldopa—Psychotic disorder—Sibutramine—obesity	0.000233	0.00433	CcSEcCtD
Methyldopa—Eczema—Bupropion—obesity	0.000231	0.0043	CcSEcCtD
Methyldopa—Headache—Methamphetamine—obesity	0.000231	0.0043	CcSEcCtD
Methyldopa—Arthralgia—Cimetidine—obesity	0.000229	0.00425	CcSEcCtD
Methyldopa—Myalgia—Cimetidine—obesity	0.000229	0.00425	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Phentermine—obesity	0.000228	0.00425	CcSEcCtD
Methyldopa—Nasal congestion—Bupropion—obesity	0.000228	0.00424	CcSEcCtD
Methyldopa—Constipation—Phentermine—obesity	0.000226	0.00421	CcSEcCtD
Methyldopa—Libido decreased—Bupropion—obesity	0.000224	0.00417	CcSEcCtD
Methyldopa—Headache—Benzphetamine—obesity	0.000223	0.00414	CcSEcCtD
Methyldopa—Breast disorder—Orlistat—obesity	0.000222	0.00414	CcSEcCtD
Methyldopa—Diarrhoea—Phendimetrazine—obesity	0.000222	0.00412	CcSEcCtD
Methyldopa—Liver function test abnormal—Sibutramine—obesity	0.00022	0.00409	CcSEcCtD
Methyldopa—Endocrine disorder—Topiramate—obesity	0.00022	0.00409	CcSEcCtD
Methyldopa—Orthostatic hypotension—Sibutramine—obesity	0.000217	0.00405	CcSEcCtD
Methyldopa—Thrombocytopenia—Cimetidine—obesity	0.000214	0.00399	CcSEcCtD
Methyldopa—Abdominal distension—Orlistat—obesity	0.000214	0.00399	CcSEcCtD
Methyldopa—Dizziness—Phendimetrazine—obesity	0.000214	0.00398	CcSEcCtD
Methyldopa—Nausea—Benzphetamine—obesity	0.000211	0.00393	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Diethylpropion—obesity	0.00021	0.0039	CcSEcCtD
Methyldopa—Pancreatitis—Orlistat—obesity	0.000209	0.00388	CcSEcCtD
Methyldopa—Amenorrhoea—Topiramate—obesity	0.000207	0.00386	CcSEcCtD
Methyldopa—Abdominal distension—Sibutramine—obesity	0.000207	0.00386	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Bupropion—obesity	0.000206	0.00383	CcSEcCtD
Methyldopa—Eosinophilia—Sibutramine—obesity	0.000204	0.00379	CcSEcCtD
Methyldopa—Hypersensitivity—Phenylpropanolamine—obesity	0.000204	0.00379	CcSEcCtD
Methyldopa—Headache—Phendimetrazine—obesity	0.000203	0.00378	CcSEcCtD
Methyldopa—Psychotic disorder—Bupropion—obesity	0.000203	0.00377	CcSEcCtD
Methyldopa—Angina pectoris—Sibutramine—obesity	0.0002	0.00373	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cimetidine—obesity	0.0002	0.00371	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Diethylpropion—obesity	0.000199	0.0037	CcSEcCtD
Methyldopa—ADRA2A—pituitary gland—obesity	0.000197	0.0199	CbGeAlD
Methyldopa—Constipation—Diethylpropion—obesity	0.000197	0.00366	CcSEcCtD
Methyldopa—ADRA2A—adipose tissue—obesity	0.000196	0.0199	CbGeAlD
Methyldopa—Nausea—Phendimetrazine—obesity	0.000192	0.00358	CcSEcCtD
Methyldopa—Asthenia—Phentermine—obesity	0.00019	0.00353	CcSEcCtD
Methyldopa—Infestation—Orlistat—obesity	0.00019	0.00353	CcSEcCtD
Methyldopa—Infestation NOS—Orlistat—obesity	0.00019	0.00353	CcSEcCtD
Methyldopa—Orthostatic hypotension—Bupropion—obesity	0.00019	0.00353	CcSEcCtD
Methyldopa—Erectile dysfunction—Sibutramine—obesity	0.00019	0.00353	CcSEcCtD
Methyldopa—Breast disorder—Bupropion—obesity	0.000188	0.00349	CcSEcCtD
Methyldopa—Constipation—Cimetidine—obesity	0.000187	0.00349	CcSEcCtD
Methyldopa—Weight increased—Sibutramine—obesity	0.000187	0.00349	CcSEcCtD
Methyldopa—Dizziness—Phenylpropanolamine—obesity	0.000183	0.0034	CcSEcCtD
Methyldopa—Diarrhoea—Phentermine—obesity	0.000181	0.00337	CcSEcCtD
Methyldopa—Abdominal distension—Bupropion—obesity	0.000181	0.00336	CcSEcCtD
Methyldopa—Hepatobiliary disease—Orlistat—obesity	0.000179	0.00334	CcSEcCtD
Methyldopa—ADRA2A—adrenal gland—obesity	0.000176	0.0178	CbGeAlD
Methyldopa—Pancreatitis—Bupropion—obesity	0.000176	0.00327	CcSEcCtD
Methyldopa—Vomiting—Phenylpropanolamine—obesity	0.000176	0.00327	CcSEcCtD
Methyldopa—Dizziness—Phentermine—obesity	0.000175	0.00326	CcSEcCtD
Methyldopa—Rash—Phenylpropanolamine—obesity	0.000174	0.00325	CcSEcCtD
Methyldopa—Dermatitis—Phenylpropanolamine—obesity	0.000174	0.00324	CcSEcCtD
Methyldopa—Body temperature increased—Cimetidine—obesity	0.000173	0.00322	CcSEcCtD
Methyldopa—Pancytopenia—Bupropion—obesity	0.00017	0.00317	CcSEcCtD
Methyldopa—Hepatitis—Orlistat—obesity	0.00017	0.00317	CcSEcCtD
Methyldopa—Vomiting—Phentermine—obesity	0.000168	0.00313	CcSEcCtD
Methyldopa—Bradycardia—Sibutramine—obesity	0.000168	0.00312	CcSEcCtD
Methyldopa—Rash—Phentermine—obesity	0.000167	0.00311	CcSEcCtD
Methyldopa—Dermatitis—Phentermine—obesity	0.000167	0.0031	CcSEcCtD
Methyldopa—Headache—Phentermine—obesity	0.000166	0.00309	CcSEcCtD
Methyldopa—Erectile dysfunction—Bupropion—obesity	0.000165	0.00308	CcSEcCtD
Methyldopa—Nausea—Phenylpropanolamine—obesity	0.000164	0.00306	CcSEcCtD
Methyldopa—Weight increased—Bupropion—obesity	0.000163	0.00304	CcSEcCtD
Methyldopa—Hypersensitivity—Cimetidine—obesity	0.000161	0.003	CcSEcCtD
Methyldopa—Infestation—Bupropion—obesity	0.00016	0.00298	CcSEcCtD
Methyldopa—Infestation NOS—Bupropion—obesity	0.00016	0.00298	CcSEcCtD
Methyldopa—Diarrhoea—Diethylpropion—obesity	0.000158	0.00293	CcSEcCtD
Methyldopa—Nausea—Phentermine—obesity	0.000157	0.00293	CcSEcCtD
Methyldopa—Asthenia—Cimetidine—obesity	0.000157	0.00293	CcSEcCtD
Methyldopa—Jaundice—Bupropion—obesity	0.000156	0.0029	CcSEcCtD
Methyldopa—Mediastinal disorder—Orlistat—obesity	0.000153	0.00286	CcSEcCtD
Methyldopa—ADRA2A—endocrine gland—obesity	0.000153	0.0154	CbGeAlD
Methyldopa—Dizziness—Diethylpropion—obesity	0.000152	0.00283	CcSEcCtD
Methyldopa—Diarrhoea—Cimetidine—obesity	0.00015	0.00279	CcSEcCtD
Methyldopa—Angiopathy—Sibutramine—obesity	0.000149	0.00278	CcSEcCtD
Methyldopa—Mental disorder—Orlistat—obesity	0.000149	0.00278	CcSEcCtD
Methyldopa—Eczema—Topiramate—obesity	0.000147	0.00274	CcSEcCtD
Methyldopa—Vomiting—Diethylpropion—obesity	0.000146	0.00272	CcSEcCtD
Methyldopa—Flatulence—Orlistat—obesity	0.000146	0.00272	CcSEcCtD
Methyldopa—Nasal congestion—Topiramate—obesity	0.000145	0.0027	CcSEcCtD
Methyldopa—Rash—Diethylpropion—obesity	0.000145	0.0027	CcSEcCtD
Methyldopa—Dermatitis—Diethylpropion—obesity	0.000145	0.0027	CcSEcCtD
Methyldopa—Dizziness—Cimetidine—obesity	0.000145	0.0027	CcSEcCtD
Methyldopa—Headache—Diethylpropion—obesity	0.000144	0.00268	CcSEcCtD
Methyldopa—Hepatitis—Bupropion—obesity	0.000144	0.00267	CcSEcCtD
Methyldopa—Libido decreased—Topiramate—obesity	0.000143	0.00265	CcSEcCtD
Methyldopa—Flatulence—Sibutramine—obesity	0.000141	0.00263	CcSEcCtD
Methyldopa—Connective tissue disorder—Bupropion—obesity	0.000141	0.00263	CcSEcCtD
Methyldopa—Droxidopa—ADRB3—obesity	0.000141	0.057	CrCbGaD
Methyldopa—Isoetarine—ADRB1—obesity	0.00014	0.0565	CrCbGaD
Methyldopa—Vomiting—Cimetidine—obesity	0.000139	0.00259	CcSEcCtD
Methyldopa—Rash—Cimetidine—obesity	0.000138	0.00257	CcSEcCtD
Methyldopa—Dermatitis—Cimetidine—obesity	0.000138	0.00257	CcSEcCtD
Methyldopa—Headache—Cimetidine—obesity	0.000137	0.00255	CcSEcCtD
Methyldopa—Nausea—Diethylpropion—obesity	0.000137	0.00255	CcSEcCtD
Methyldopa—Cardiac disorder—Bupropion—obesity	0.000133	0.00248	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Topiramate—obesity	0.000131	0.00244	CcSEcCtD
Methyldopa—Angiopathy—Bupropion—obesity	0.00013	0.00243	CcSEcCtD
Methyldopa—Nausea—Cimetidine—obesity	0.00013	0.00242	CcSEcCtD
Methyldopa—Mediastinal disorder—Bupropion—obesity	0.000129	0.00241	CcSEcCtD
Methyldopa—Psychotic disorder—Topiramate—obesity	0.000129	0.0024	CcSEcCtD
Methyldopa—Leukopenia—Sibutramine—obesity	0.000128	0.00239	CcSEcCtD
Methyldopa—Isoprenaline—ADRB3—obesity	0.000128	0.0518	CrCbGaD
Methyldopa—Myalgia—Orlistat—obesity	0.000126	0.00235	CcSEcCtD
Methyldopa—Mental disorder—Bupropion—obesity	0.000126	0.00234	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000125	0.00233	CcSEcCtD
Methyldopa—Flatulence—Bupropion—obesity	0.000123	0.00229	CcSEcCtD
Methyldopa—Liver function test abnormal—Topiramate—obesity	0.000122	0.00227	CcSEcCtD
Methyldopa—Arthralgia—Sibutramine—obesity	0.000122	0.00227	CcSEcCtD
Methyldopa—Myalgia—Sibutramine—obesity	0.000122	0.00227	CcSEcCtD
Methyldopa—Oedema—Orlistat—obesity	0.000121	0.00225	CcSEcCtD
Methyldopa—Orthostatic hypotension—Topiramate—obesity	0.000121	0.00225	CcSEcCtD
Methyldopa—Infection—Orlistat—obesity	0.00012	0.00224	CcSEcCtD
Methyldopa—Breast disorder—Topiramate—obesity	0.00012	0.00222	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Topiramate—obesity	0.000119	0.00222	CcSEcCtD
Methyldopa—Norepinephrine—ADRB3—obesity	0.000119	0.048	CrCbGaD
Methyldopa—Nervous system disorder—Orlistat—obesity	0.000119	0.00221	CcSEcCtD
Methyldopa—Skin disorder—Orlistat—obesity	0.000117	0.00219	CcSEcCtD
Methyldopa—Isoetarine—ADRB2—obesity	0.000117	0.0475	CrCbGaD
Methyldopa—Oedema—Sibutramine—obesity	0.000117	0.00218	CcSEcCtD
Methyldopa—Infection—Sibutramine—obesity	0.000116	0.00216	CcSEcCtD
Methyldopa—Abdominal distension—Topiramate—obesity	0.000115	0.00214	CcSEcCtD
Methyldopa—Thrombocytopenia—Sibutramine—obesity	0.000115	0.00213	CcSEcCtD
Methyldopa—Skin disorder—Sibutramine—obesity	0.000114	0.00212	CcSEcCtD
Methyldopa—Eosinophilia—Topiramate—obesity	0.000113	0.00211	CcSEcCtD
Methyldopa—Pancreatitis—Topiramate—obesity	0.000112	0.00209	CcSEcCtD
Methyldopa—Leukopenia—Bupropion—obesity	0.000112	0.00208	CcSEcCtD
Methyldopa—Angina pectoris—Topiramate—obesity	0.000111	0.00207	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Orlistat—obesity	0.00011	0.00205	CcSEcCtD
Methyldopa—Paraesthesia—Orlistat—obesity	0.000109	0.00202	CcSEcCtD
Methyldopa—Pancytopenia—Topiramate—obesity	0.000109	0.00202	CcSEcCtD
Methyldopa—Epinephrine—ADRB3—obesity	0.000108	0.0436	CrCbGaD
Methyldopa—Musculoskeletal discomfort—Sibutramine—obesity	0.000107	0.00198	CcSEcCtD
Methyldopa—Myalgia—Bupropion—obesity	0.000106	0.00198	CcSEcCtD
Methyldopa—Arthralgia—Bupropion—obesity	0.000106	0.00198	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000106	0.00197	CcSEcCtD
Methyldopa—Erectile dysfunction—Topiramate—obesity	0.000105	0.00196	CcSEcCtD
Methyldopa—Paraesthesia—Sibutramine—obesity	0.000105	0.00196	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Orlistat—obesity	0.000104	0.00194	CcSEcCtD
Methyldopa—Weight increased—Topiramate—obesity	0.000104	0.00194	CcSEcCtD
Methyldopa—Oedema—Bupropion—obesity	0.000102	0.0019	CcSEcCtD
Methyldopa—Infestation—Topiramate—obesity	0.000102	0.0019	CcSEcCtD
Methyldopa—Infestation NOS—Topiramate—obesity	0.000102	0.0019	CcSEcCtD
Methyldopa—Infection—Bupropion—obesity	0.000101	0.00189	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Sibutramine—obesity	0.000101	0.00188	CcSEcCtD
Methyldopa—Constipation—Sibutramine—obesity	0.0001	0.00186	CcSEcCtD
Methyldopa—Nervous system disorder—Bupropion—obesity	0.0001	0.00186	CcSEcCtD
Methyldopa—Thrombocytopenia—Bupropion—obesity	9.99e-05	0.00186	CcSEcCtD
Methyldopa—Skin disorder—Bupropion—obesity	9.91e-05	0.00184	CcSEcCtD
Methyldopa—Body temperature increased—Orlistat—obesity	9.56e-05	0.00178	CcSEcCtD
Methyldopa—Agranulocytosis—Topiramate—obesity	9.51e-05	0.00177	CcSEcCtD
Methyldopa—Bradycardia—Topiramate—obesity	9.31e-05	0.00173	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Bupropion—obesity	9.3e-05	0.00173	CcSEcCtD
Methyldopa—Body temperature increased—Sibutramine—obesity	9.25e-05	0.00172	CcSEcCtD
Methyldopa—Paraesthesia—Bupropion—obesity	9.16e-05	0.00171	CcSEcCtD
Methyldopa—Hepatitis—Topiramate—obesity	9.15e-05	0.0017	CcSEcCtD
Methyldopa—Mesalazine—PPARG—obesity	9.03e-05	0.0365	CrCbGaD
Methyldopa—Connective tissue disorder—Topiramate—obesity	8.99e-05	0.00167	CcSEcCtD
Methyldopa—Hypersensitivity—Orlistat—obesity	8.91e-05	0.00166	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Bupropion—obesity	8.81e-05	0.00164	CcSEcCtD
Methyldopa—Constipation—Bupropion—obesity	8.73e-05	0.00162	CcSEcCtD
Methyldopa—Asthenia—Orlistat—obesity	8.68e-05	0.00162	CcSEcCtD
Methyldopa—Hypersensitivity—Sibutramine—obesity	8.62e-05	0.00161	CcSEcCtD
Methyldopa—Cardiac disorder—Topiramate—obesity	8.49e-05	0.00158	CcSEcCtD
Methyldopa—Asthenia—Sibutramine—obesity	8.4e-05	0.00156	CcSEcCtD
Methyldopa—Angiopathy—Topiramate—obesity	8.3e-05	0.00155	CcSEcCtD
Methyldopa—Diarrhoea—Orlistat—obesity	8.27e-05	0.00154	CcSEcCtD
Methyldopa—Mediastinal disorder—Topiramate—obesity	8.25e-05	0.00153	CcSEcCtD
Methyldopa—Body temperature increased—Bupropion—obesity	8.07e-05	0.0015	CcSEcCtD
Methyldopa—Mental disorder—Topiramate—obesity	8.02e-05	0.00149	CcSEcCtD
Methyldopa—Diarrhoea—Sibutramine—obesity	8.01e-05	0.00149	CcSEcCtD
Methyldopa—Dizziness—Orlistat—obesity	8e-05	0.00149	CcSEcCtD
Methyldopa—Flatulence—Topiramate—obesity	7.85e-05	0.00146	CcSEcCtD
Methyldopa—Dopamine—COMT—obesity	7.84e-05	0.0317	CrCbGaD
Methyldopa—Dizziness—Sibutramine—obesity	7.74e-05	0.00144	CcSEcCtD
Methyldopa—Vomiting—Orlistat—obesity	7.69e-05	0.00143	CcSEcCtD
Methyldopa—Rash—Orlistat—obesity	7.63e-05	0.00142	CcSEcCtD
Methyldopa—Dermatitis—Orlistat—obesity	7.62e-05	0.00142	CcSEcCtD
Methyldopa—Headache—Orlistat—obesity	7.58e-05	0.00141	CcSEcCtD
Methyldopa—Hypersensitivity—Bupropion—obesity	7.52e-05	0.0014	CcSEcCtD
Methyldopa—Vomiting—Sibutramine—obesity	7.44e-05	0.00139	CcSEcCtD
Methyldopa—Rash—Sibutramine—obesity	7.38e-05	0.00137	CcSEcCtD
Methyldopa—Dermatitis—Sibutramine—obesity	7.37e-05	0.00137	CcSEcCtD
Methyldopa—Headache—Sibutramine—obesity	7.33e-05	0.00136	CcSEcCtD
Methyldopa—Asthenia—Bupropion—obesity	7.32e-05	0.00136	CcSEcCtD
Methyldopa—Nausea—Orlistat—obesity	7.18e-05	0.00134	CcSEcCtD
Methyldopa—Leukopenia—Topiramate—obesity	7.13e-05	0.00133	CcSEcCtD
Methyldopa—Norepinephrine—SLC22A1—obesity	7.08e-05	0.0286	CrCbGaD
Methyldopa—Diarrhoea—Bupropion—obesity	6.98e-05	0.0013	CcSEcCtD
Methyldopa—Nausea—Sibutramine—obesity	6.95e-05	0.00129	CcSEcCtD
Methyldopa—L-DOPA—DRD4—obesity	6.83e-05	0.0276	CrCbGaD
Methyldopa—Myalgia—Topiramate—obesity	6.78e-05	0.00126	CcSEcCtD
Methyldopa—Arthralgia—Topiramate—obesity	6.78e-05	0.00126	CcSEcCtD
Methyldopa—Dizziness—Bupropion—obesity	6.75e-05	0.00126	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	6.73e-05	0.00125	CcSEcCtD
Methyldopa—Dopamine—SLC22A1—obesity	6.58e-05	0.0266	CrCbGaD
Methyldopa—Oedema—Topiramate—obesity	6.5e-05	0.00121	CcSEcCtD
Methyldopa—Vomiting—Bupropion—obesity	6.49e-05	0.00121	CcSEcCtD
Methyldopa—Infection—Topiramate—obesity	6.46e-05	0.0012	CcSEcCtD
Methyldopa—Rash—Bupropion—obesity	6.43e-05	0.0012	CcSEcCtD
Methyldopa—Dermatitis—Bupropion—obesity	6.43e-05	0.0012	CcSEcCtD
Methyldopa—Epinephrine—SLC22A1—obesity	6.42e-05	0.026	CrCbGaD
Methyldopa—Headache—Bupropion—obesity	6.39e-05	0.00119	CcSEcCtD
Methyldopa—Droxidopa—ADRB1—obesity	6.38e-05	0.0258	CrCbGaD
Methyldopa—Nervous system disorder—Topiramate—obesity	6.38e-05	0.00119	CcSEcCtD
Methyldopa—Thrombocytopenia—Topiramate—obesity	6.36e-05	0.00118	CcSEcCtD
Methyldopa—Dopamine—DRD4—obesity	6.35e-05	0.0257	CrCbGaD
Methyldopa—Skin disorder—Topiramate—obesity	6.31e-05	0.00118	CcSEcCtD
Methyldopa—Nausea—Bupropion—obesity	6.06e-05	0.00113	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Topiramate—obesity	5.92e-05	0.0011	CcSEcCtD
Methyldopa—Paraesthesia—Topiramate—obesity	5.84e-05	0.00109	CcSEcCtD
Methyldopa—Isoprenaline—ADRB1—obesity	5.8e-05	0.0234	CrCbGaD
Methyldopa—L-DOPA—DRD1—obesity	5.78e-05	0.0234	CrCbGaD
Methyldopa—Gastrointestinal disorder—Topiramate—obesity	5.61e-05	0.00104	CcSEcCtD
Methyldopa—Constipation—Topiramate—obesity	5.56e-05	0.00103	CcSEcCtD
Methyldopa—Dopamine—DRD1—obesity	5.38e-05	0.0217	CrCbGaD
Methyldopa—Norepinephrine—ADRB1—obesity	5.37e-05	0.0217	CrCbGaD
Methyldopa—Droxidopa—ADRB2—obesity	5.36e-05	0.0217	CrCbGaD
Methyldopa—Body temperature increased—Topiramate—obesity	5.14e-05	0.000957	CcSEcCtD
Methyldopa—Dopamine—ADRB1—obesity	4.99e-05	0.0202	CrCbGaD
Methyldopa—Isoprenaline—ADRB2—obesity	4.88e-05	0.0197	CrCbGaD
Methyldopa—Epinephrine—ADRB1—obesity	4.87e-05	0.0197	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS2—obesity	4.86e-05	0.0196	CrCbGaD
Methyldopa—Hypersensitivity—Topiramate—obesity	4.79e-05	0.000892	CcSEcCtD
Methyldopa—Asthenia—Topiramate—obesity	4.66e-05	0.000868	CcSEcCtD
Methyldopa—Epinephrine—TNF—obesity	4.62e-05	0.0187	CrCbGaD
Methyldopa—Norepinephrine—ADRB2—obesity	4.52e-05	0.0183	CrCbGaD
Methyldopa—Diarrhoea—Topiramate—obesity	4.45e-05	0.000828	CcSEcCtD
Methyldopa—Dizziness—Topiramate—obesity	4.3e-05	0.0008	CcSEcCtD
Methyldopa—Vomiting—Topiramate—obesity	4.13e-05	0.000769	CcSEcCtD
Methyldopa—Rash—Topiramate—obesity	4.1e-05	0.000763	CcSEcCtD
Methyldopa—Epinephrine—ADRB2—obesity	4.1e-05	0.0166	CrCbGaD
Methyldopa—Dermatitis—Topiramate—obesity	4.1e-05	0.000762	CcSEcCtD
Methyldopa—Norepinephrine—DRD2—obesity	4.08e-05	0.0165	CrCbGaD
Methyldopa—L-DOPA—DRD2—obesity	4.08e-05	0.0165	CrCbGaD
Methyldopa—Headache—Topiramate—obesity	4.07e-05	0.000758	CcSEcCtD
Methyldopa—Nausea—Topiramate—obesity	3.86e-05	0.000719	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—obesity	3.81e-05	0.0154	CrCbGaD
Methyldopa—Dopamine—SLC6A4—obesity	3.81e-05	0.0154	CrCbGaD
Methyldopa—Dopamine—DRD2—obesity	3.79e-05	0.0153	CrCbGaD
Methyldopa—ADRA2A—Signaling Pathways—PPY—obesity	7.31e-06	0.000208	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SREBF2—obesity	7.29e-06	0.000208	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HK1—obesity	7.29e-06	0.000208	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NPS—obesity	7.24e-06	0.000207	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—obesity	7.2e-06	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC8—obesity	7.17e-06	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCH—obesity	7.17e-06	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GIP—obesity	7.17e-06	0.000205	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAV1—obesity	7.13e-06	0.000203	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOA1—obesity	7.12e-06	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD1—obesity	7.1e-06	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2C—obesity	7.1e-06	0.000203	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—obesity	7.06e-06	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPA—obesity	7.04e-06	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR1—obesity	7.02e-06	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAV1—obesity	6.99e-06	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOA1—obesity	6.98e-06	0.000199	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—obesity	6.97e-06	0.000199	CbGpPWpGaD
Methyldopa—DDC—Metabolism—INS—obesity	6.93e-06	0.000198	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPIN1—obesity	6.89e-06	0.000197	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB1—obesity	6.88e-06	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD2—obesity	6.85e-06	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEPR—obesity	6.81e-06	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—obesity	6.78e-06	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GCG—obesity	6.78e-06	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—obesity	6.78e-06	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA5—obesity	6.75e-06	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GHRL—obesity	6.73e-06	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD4—obesity	6.68e-06	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PRKCB—obesity	6.66e-06	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—F2—obesity	6.66e-06	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—obesity	6.63e-06	0.000189	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—obesity	6.5e-06	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CLOCK—obesity	6.44e-06	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC22A1—obesity	6.44e-06	0.000184	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—obesity	6.43e-06	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR1—obesity	6.38e-06	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—obesity	6.37e-06	0.000182	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—obesity	6.35e-06	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SULT2A1—obesity	6.28e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GLP1R—obesity	6.28e-06	0.000179	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—obesity	6.27e-06	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD2—obesity	6.22e-06	0.000177	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—obesity	6.19e-06	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DPYD—obesity	6.17e-06	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GCG—obesity	6.16e-06	0.000176	CbGpPWpGaD
Methyldopa—COMT—Metabolism—INS—obesity	6.15e-06	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADRB2—obesity	6.14e-06	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB3—obesity	6.1e-06	0.000174	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—obesity	6.08e-06	0.000173	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3R1—obesity	6.08e-06	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GAL—obesity	5.96e-06	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PRKAR2B—obesity	5.94e-06	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DCN—obesity	5.9e-06	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C5AR1—obesity	5.89e-06	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNB3—obesity	5.84e-06	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—obesity	5.83e-06	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT2—obesity	5.83e-06	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—obesity	5.77e-06	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CPT1A—obesity	5.74e-06	0.000164	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—obesity	5.71e-06	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNAS—obesity	5.69e-06	0.000162	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—obesity	5.64e-06	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NAMPT—obesity	5.63e-06	0.000161	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—obesity	5.61e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—obesity	5.6e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LIPC—obesity	5.59e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCK—obesity	5.59e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB2—obesity	5.57e-06	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOC3—obesity	5.56e-06	0.000159	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—obesity	5.56e-06	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—obesity	5.54e-06	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—obesity	5.53e-06	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCL5—obesity	5.44e-06	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CETP—obesity	5.4e-06	0.000154	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—obesity	5.39e-06	0.000154	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3R1—obesity	5.39e-06	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCK—obesity	5.39e-06	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKG1—obesity	5.39e-06	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RHOA—obesity	5.34e-06	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SDC1—obesity	5.34e-06	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNB3—obesity	5.31e-06	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3R1—obesity	5.29e-06	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—obesity	5.29e-06	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKR1C3—obesity	5.25e-06	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RBP4—obesity	5.25e-06	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLP1R—obesity	5.25e-06	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SCARB1—obesity	5.17e-06	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNAS—obesity	5.17e-06	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCKAR—obesity	5.16e-06	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRH3—obesity	5.16e-06	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SREBF1—obesity	5.02e-06	0.000143	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—obesity	4.98e-06	0.000142	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKAR2B—obesity	4.97e-06	0.000142	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL5—obesity	4.94e-06	0.000141	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—obesity	4.93e-06	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCD—obesity	4.9e-06	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT2—obesity	4.88e-06	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—obesity	4.88e-06	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCF2—obesity	4.8e-06	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—obesity	4.8e-06	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C3—obesity	4.79e-06	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FASN—obesity	4.78e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—obesity	4.76e-06	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—obesity	4.72e-06	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPY—obesity	4.68e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOC3—obesity	4.65e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IAPP—obesity	4.65e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2E1—obesity	4.59e-06	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—obesity	4.55e-06	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NQO1—obesity	4.54e-06	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1B—obesity	4.51e-06	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CRH—obesity	4.51e-06	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SDC1—obesity	4.46e-06	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCD—obesity	4.45e-06	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKR1C3—obesity	4.39e-06	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—obesity	4.36e-06	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C3—obesity	4.35e-06	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A4—obesity	4.35e-06	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCG—obesity	4.35e-06	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYCS—obesity	4.29e-06	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPS—obesity	4.28e-06	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GGT1—obesity	4.21e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT1—obesity	4.21e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2—obesity	4.21e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCB—obesity	4.21e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD1—obesity	4.2e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2C—obesity	4.2e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA1—obesity	4.15e-06	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—obesity	4.13e-06	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STK11—obesity	4.09e-06	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP19A1—obesity	4.09e-06	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTRK2—obesity	4.08e-06	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB1—obesity	4.06e-06	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—obesity	4.03e-06	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PARP1—obesity	3.98e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHRL—obesity	3.98e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD4—obesity	3.94e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—obesity	3.83e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCB—obesity	3.82e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2—obesity	3.82e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COMT—obesity	3.8e-06	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR1—obesity	3.77e-06	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNB3—obesity	3.75e-06	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARGC1A—obesity	3.75e-06	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—obesity	3.73e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TCF7L2—obesity	3.7e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT2—obesity	3.68e-06	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD2—obesity	3.67e-06	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—obesity	3.66e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNAS—obesity	3.65e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN1—obesity	3.64e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GCG—obesity	3.64e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOB—obesity	3.58e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—obesity	3.54e-06	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—obesity	3.5e-06	9.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—obesity	3.48e-06	9.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRL—obesity	3.47e-06	9.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STK11—obesity	3.42e-06	9.76e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—obesity	3.42e-06	9.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPL—obesity	3.41e-06	9.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—obesity	3.4e-06	9.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLG—obesity	3.38e-06	9.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RHOA—obesity	3.38e-06	9.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT2—obesity	3.34e-06	9.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3R1—obesity	3.34e-06	9.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—obesity	3.33e-06	9.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO3—obesity	3.3e-06	9.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB2—obesity	3.29e-06	9.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD36—obesity	3.24e-06	9.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS1—obesity	3.24e-06	9.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—obesity	3.21e-06	9.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS3—obesity	3.2e-06	9.14e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNB3—obesity	3.14e-06	8.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—TYK2—obesity	3.09e-06	8.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—obesity	3.08e-06	8.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF2—obesity	3.08e-06	8.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—obesity	3.07e-06	8.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RHOA—obesity	3.07e-06	8.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNAS—obesity	3.05e-06	8.71e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—obesity	3.04e-06	8.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3R1—obesity	3.03e-06	8.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARA—obesity	3.02e-06	8.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOB—obesity	2.99e-06	8.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—obesity	2.98e-06	8.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—obesity	2.92e-06	8.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL5—obesity	2.92e-06	8.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—obesity	2.86e-06	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPL—obesity	2.85e-06	8.14e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—obesity	2.84e-06	8.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO1—obesity	2.83e-06	8.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RPS6KB1—obesity	2.83e-06	8.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—obesity	2.83e-06	8.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—obesity	2.8e-06	7.99e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—obesity	2.79e-06	7.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCD—obesity	2.63e-06	7.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—obesity	2.58e-06	7.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—obesity	2.57e-06	7.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C3—obesity	2.57e-06	7.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—obesity	2.49e-06	7.11e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—obesity	2.48e-06	7.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—obesity	2.46e-06	7.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS2—obesity	2.45e-06	6.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—INS—obesity	2.44e-06	6.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—obesity	2.44e-06	6.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—obesity	2.43e-06	6.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—obesity	2.39e-06	6.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—obesity	2.39e-06	6.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—obesity	2.37e-06	6.76e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—obesity	2.37e-06	6.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—obesity	2.28e-06	6.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—obesity	2.27e-06	6.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCB—obesity	2.26e-06	6.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2—obesity	2.26e-06	6.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—obesity	2.24e-06	6.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BAD—obesity	2.23e-06	6.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—obesity	2.16e-06	6.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—obesity	2.14e-06	6.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3R1—obesity	2.14e-06	6.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS1—obesity	2.13e-06	6.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—obesity	2.06e-06	5.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—INS—obesity	2.04e-06	5.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—obesity	2.01e-06	5.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—obesity	1.98e-06	5.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—obesity	1.98e-06	5.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT2—obesity	1.98e-06	5.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—obesity	1.96e-06	5.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—obesity	1.9e-06	5.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	1.88e-06	5.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—obesity	1.88e-06	5.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TYK2—obesity	1.83e-06	5.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHOA—obesity	1.81e-06	5.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—obesity	1.79e-06	5.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3R1—obesity	1.79e-06	5.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—obesity	1.71e-06	4.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—obesity	1.65e-06	4.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—obesity	1.65e-06	4.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—obesity	1.54e-06	4.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—obesity	1.51e-06	4.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—obesity	1.44e-06	4.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK8—obesity	1.4e-06	3.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—obesity	1.39e-06	3.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—obesity	1.28e-06	3.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—obesity	1.21e-06	3.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—obesity	1.19e-06	3.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—obesity	1.19e-06	3.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—obesity	1.01e-06	2.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—obesity	9.85e-07	2.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—obesity	8.93e-07	2.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—obesity	8.24e-07	2.35e-05	CbGpPWpGaD
